{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:17:00Z","timestamp":1789816620507,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"DOI":"10.1007\/s10157-026-02939-1","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:57:12Z","timestamp":1789815432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A new frontier in edema management: the potential of tolvaptan for refractory edema with hyponatremia in pediatric nephrotic syndrome"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9678-7706","authenticated-orcid":false,"family":"Vignesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasavaradan","family":"Govindrajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"10","key":"2939_CR1","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.2215\/CJN.00380116","volume":"11","author":"THM Banh","year":"2016","unstructured":"Banh THM, Hussain-Shamsy N, Patel V, Vasilevska-Ristovska J, Borges K, Sibbald C, et al. Ethnic differences in incidence and outcomes of childhood nephrotic syndrome. Clin J Am Soc Nephrol. 2016;11(10):1760\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2939_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.33590\/emjurol\/21-00041","volume":"9","author":"P Jethwani","year":"2021","unstructured":"Jethwani P, Krishnan N. Pathogenesis and treatment of refractory edema in nephrotic syndrome. Eur Med J Urol. 2021;9(1):107\u201317. https:\/\/doi.org\/10.33590\/emjurol\/21-00041.","journal-title":"Eur Med J Urol"},{"issue":"11","key":"2939_CR3","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s11255-014-0839-2","volume":"46","author":"H Rondon-Berrios","year":"2014","unstructured":"Rondon-Berrios H, Agaba EI, Tzamaloukas AH. Hyponatremia: pathophysiology, classification, manifestations, and management. Int Urol Nephrol. 2014;46(11):2153\u201365.","journal-title":"Int Urol Nephrol"},{"issue":"8","key":"2939_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3345\/kjp.2011.54.8.322","volume":"54","author":"SJ Park","year":"2011","unstructured":"Park SJ, Shin JI. Complications of nephrotic syndrome. Korean J Pediatr. 2011;54(8):322.","journal-title":"Korean J Pediatr"},{"issue":"4","key":"2939_CR5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/cells4040622","volume":"4","author":"M Duffy","year":"2015","unstructured":"Duffy M, Jain S, Harrell N, Kothari N, Reddi A. Albumin and furosemide combination for management of edema in nephrotic syndrome: a review of clinical studies. Cells. 2015;4(4):622\u201330.","journal-title":"Cells"},{"issue":"1","key":"2939_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s10157-014-1031-9","volume":"19","author":"Y Kaku","year":"2015","unstructured":"Kaku Y, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, et al. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy. Clin Exp Nephrol. 2015;19(1):34\u201353.","journal-title":"Clin Exp Nephrol"},{"issue":"10","key":"2939_CR7","first-page":"543","volume":"34","author":"T Reilly","year":"2009","unstructured":"Reilly T, Chavez B. Tolvaptan (Samsca) for hyponatremia: is it worth its salt? P T. 2009;34(10):543\u20137.","journal-title":"P T"},{"issue":"20","key":"2939_CR8","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099\u2013112. https:\/\/doi.org\/10.1056\/NEJMoa065181.","journal-title":"N Engl J Med"},{"issue":"4","key":"2939_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2009080857","volume":"21","author":"T Berl","year":"2010","unstructured":"Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS. SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21(4):705\u201312. https:\/\/doi.org\/10.1681\/ASN.2009080857","journal-title":"J Am Soc Nephrol"},{"key":"2939_CR10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"O Devuyst","year":"2017","unstructured":"Devuyst O. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J Am Soc Nephrol. 2017;28:1592\u2013602.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2939_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297(12):1319.","journal-title":"JAMA"},{"issue":"6","key":"2939_CR12","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10157-018-1603-1","volume":"22","author":"N Tominaga","year":"2018","unstructured":"Tominaga N, Kida K, Inomata T, Sato N, Izumi T, Akashi YJ, et al. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study. Clin Exp Nephrol. 2018;22(6):1395\u2013403.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"2939_CR13","first-page":"494","volume":"23","author":"AY Koksoy","year":"2018","unstructured":"Koksoy AY, Kurtul M, Ozsahin AK, Cayci FS, Tayfun M, Bayrakci US. Tolvaptan use to treat SIADH in a child. J Pediatr Pharmacol Ther. 2018;23(6):494\u20138.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"2939_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00246-013-0671-y","volume":"34","author":"RB Regen","year":"2013","unstructured":"Regen RB, Gonzalez A, Zawodniak K, Leonard D, Quigley R, Barnes AP, et al. Tolvaptan increases serum sodium in pediatric patients with heart failure. Pediatr Cardiol. 2013;34(6):1463\u20138.","journal-title":"Pediatr Cardiol"},{"issue":"7","key":"2939_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00431-019-03384-x","volume":"178","author":"F Schaefer","year":"2019","unstructured":"Schaefer F, Mekahli D, Emma F, Gilbert RD, Bockenhauer D, Cadnapaphornchai MA, et al. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Eur J Pediatr. 2019;178(7):1013\u201321.","journal-title":"Eur J Pediatr"},{"issue":"7","key":"2939_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12098-021-03988-y","volume":"89","author":"J Meena","year":"2022","unstructured":"Meena J, Hari P, Sinha A, Bagga A. Efficacy and safety of combination therapy with tolvaptan and furosemide in children with nephrotic syndrome and refractory edema: a prospective interventional study. Indian J Pediatr. 2022;89(7):699\u2013705.","journal-title":"Indian J Pediatr"},{"issue":"5","key":"2939_CR17","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2215\/CJN.04390808","volume":"4","author":"G Kapur","year":"2009","unstructured":"Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone\u2014a prospective study. Clin J Am Soc Nephrol. 2009;4(5):907\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2939_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2939_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/ki.1984.34","volume":"25","author":"M Usberti","year":"1984","unstructured":"Usberti M, Federico S, Meccariello S, Cianciaruso B, Balletta M, Pecoraro C, et al. Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int. 1984;25(2):422\u20139.","journal-title":"Kidney Int"},{"key":"2939_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/IJNRD.S177469","volume":"11","author":"M Brovko","year":"2018","unstructured":"Brovko M, Kozlovskaya L, Pulin A, Moiseev S, Sholomova V, Shchekochikhin D, et al. Low aquaporin-2 excretion in the nephrotic syndrome: an escape from the vasopressin regulating effect. Int J Nephrol Renovasc Dis. 2018;11:271\u20137.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2939_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1681\/ASN.V8115","volume":"8","author":"E Apostol","year":"1997","unstructured":"Apostol E, Ecelbarger CA, Terris J, Bradford AD, Andrews P, Knepper MA. Reduced renal medullary water channel expression in puromycin aminonucleoside-induced nephrotic syndrome. J Am Soc Nephrol. 1997;8:15\u201324.","journal-title":"J Am Soc Nephrol"},{"key":"2939_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00228-011-1006-7","volume":"67","author":"N Gassanov","year":"2011","unstructured":"Gassanov N, Semmo N, Semmo M, Nia AM, Fuhr U, Er F. Arginine vasopressin and treatment with vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and SIADH. Eur J Clin Pharmacol. 2011;67:333\u201346.","journal-title":"Eur J Clin Pharmacol"},{"key":"2939_CR23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/jc.2012-4082","volume":"98","author":"A Peri","year":"2013","unstructured":"Peri A. Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab. 2013;98:1321\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2939_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4274\/jcrpe.4531","volume":"9","author":"G Tuli","year":"2017","unstructured":"Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P. Tolvaptan treatment in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion: a report of three cases. J Clin Res Pediatr Endocrinol. 2017;9(3):288.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"4","key":"2939_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s13730-021-00601-1","volume":"10","author":"M Saimiya","year":"2021","unstructured":"Saimiya M, Kaku Y, Nishimura M. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome. CEN Case Rep. 2021;10(4):523\u20136.","journal-title":"CEN Case Rep"},{"key":"2939_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00467-013-2687-1","volume":"29","author":"M Shimizu","year":"2014","unstructured":"Shimizu M, Ishikawa S, Yachi Y, Muraoka M, Tasaki Y, Iwasaki H, et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol. 2014;29:915\u20137.","journal-title":"Pediatr Nephrol"},{"key":"2939_CR27","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00467-020-04530-6","volume":"35","author":"JD Delbet","year":"2020","unstructured":"Delbet JD, Parmentier C, Ulinski T. Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome. Pediatr Nephrol. 2020;35:1347\u201350.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2939_CR28","doi-asserted-by":"publisher","first-page":"e00614","DOI":"10.1002\/prp2.614","volume":"8","author":"X Luo","year":"2020","unstructured":"Luo X, Jin Q, Wu Y. Tolvaptan add-on therapy in patients with acute heart failure: a systematic review and meta-analysis. Pharmacol Res Perspect. 2020;8(3):e00614. https:\/\/doi.org\/10.1002\/prp2.614.","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"2939_CR29","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/ndt\/gfad232","volume":"39","author":"T Akihisa","year":"2024","unstructured":"Akihisa T, Kataoka H, Makabe S, Manabe S, Yoshida R, Ushio Y, Sato M, Yajima A, Hanafusa N, Tsuchiya K, Nitta K, Hoshino J, Mochizuki T. Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transpl. 2024;39(6):1008\u201315. https:\/\/doi.org\/10.1093\/ndt\/gfad232.","journal-title":"Nephrol Dial Transpl"},{"issue":"22","key":"2939_CR30","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","volume":"49","author":"JE Udelson","year":"2007","unstructured":"Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O\u2019Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007;49(22):2151\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2007.01.091.","journal-title":"J Am Coll Cardiol"},{"key":"2939_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1536\/ihj.13-221","volume":"55","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels. Int Heart J. 2014;55:131\u20137.","journal-title":"Int Heart J"},{"issue":"1","key":"2939_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13613-015-0096-2","volume":"6","author":"M Umbrello","year":"2016","unstructured":"Umbrello M, Mantovani ES, Formenti P, Casiraghi C, Ottolina D, Taverna M, et al. Tolvaptan for hyponatremia with preserved sodium pool in critically ill patients. Ann Intensive Care. 2016;6(1):1\u20139. https:\/\/doi.org\/10.1186\/s13613-015-0096-2.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"2939_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.0000000000000022","volume":"18","author":"D Mekahli","year":"2023","unstructured":"Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, et al. Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: a randomized controlled trial. Clin J Am Soc Nephrol. 2023;18(1):36\u201346.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"2939_CR34","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1111\/bcp.15367","volume":"88","author":"A Piffer","year":"2022","unstructured":"Piffer A, Bianchetti MG, Leoni-Foglia C, Simonetti GD, Milani GP, Lava SA. Vaptans for oedematous and hyponatraemic disorders in childhood: a systematic literature review. Br J Clin Pharmacol. 2022;88(10):4474\u201380.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02939-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02939-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02939-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:57:13Z","timestamp":1789815433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02939-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":34,"alternative-id":["2939"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02939-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors have declared no competing interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All eligible children admitted to the centre during the study period, from February 2022 to August 2024, were invited to participate. Written informed consent was obtained from each enrolled child\u2019s parents or legal guardians. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee at which the studies\n                      (IEC\/VMMC\/SJH\/THESIS\/06\/2022\/CC-217)\n                      and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}